Photodiagnosis and Photodynamic Therapy
Volume 5, Issue 4 , Pages 285-287, December 2008

An update on the regulatory status of PDT photosensitizers in China

  • Zheng Huang, MD, PhD

      Affiliations

    • Corresponding Author InformationTel.: +1 303 239 3567; fax: +1 303 239 3562.

Department of Radiation Oncology, University of Colorado Denver, Aurora 80045, CO, USA

published online 17 February 2009.

Summary 

Numerous photosensitizers have been developed and evaluated in China. HiPorfin, a hematoporphyrin derivative (HpD) received the first regulatory approval in the early 2000s. Aila, a topical formulation containing predrug 5-aminolevulinic acid, received the regulatory approval in 2007. Recently, new drug applications have been filed for several hematoporphyrin derivatives and a zinc phthalocyanine (ZnPc) derivative. This short report will summarize the current regulatory status of Chinese photosensitizers developed for photodynamic therapy (PDT).

Keywords: Photosensitizer, Hematoporphyrin derivative, Zinc phthalocyanine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1572-1000(09)00006-4

doi:10.1016/j.pdpdt.2009.01.005

Photodiagnosis and Photodynamic Therapy
Volume 5, Issue 4 , Pages 285-287, December 2008

Article Tools

* Image Usage & Resolution